Quick Answer
CERO THERAPEUTICS HOLDINGS, INC. reported Operating Income Loss of -$15.30 million for the year ending 2024.
- CERO THERAPEUTICS HOLDINGS, INC. showed a decrease of -1,605.5% in Operating Income Loss from 2024 to 2024.
- This data is from CERO THERAPEUTICS HOLDINGS, INC.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2022 to 2024 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2022: -$376.6 thousand | Q3 2022: -$836.7 thousand | Q1 2023: -$2.44 million | Q2 2023: -$2.41 million | Q3 2023: -$429.8 thousand | Q1 2024: -$897.1 thousand | Q1 2024: -$3.65 million | Q2 2024: -$5.15 million | Q3 2024: -$4.40 million | Q1 2025: -$4.95 million | Q2 2025: -$4.72 million | Q3 2025: -$4.36 million.
- Over the full 4 years of available data (2022 to 2024), CERO THERAPEUTICS HOLDINGS, INC.'s Operating Income Loss has declined by 426.6%.
- Historical annual values: Fiscal year 2024: -$15.30 million | Fiscal year 2024: -$897.1 thousand | Fiscal year 2023: -$7.68 million | Fiscal year 2022: -$2.91 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: